Vir Biotechnology Inc

-1.27 (-2.76%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)5.84B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$75.09 Million
Adjusted EPS-$0.48
See more estimates
10-Day MA$49.12
50-Day MA$44.01
200-Day MA$46.11
See more pivots

Vir Biotechnology Inc Stock, NASDAQ:VIR

499 Illinois Street, Suite 500, San Francisco, California 94158
United States of America
Phone: +1.415.906.4324
Number of Employees: 327


Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.